Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib in mCRPC with HRD or BRCA1/2 Mutation
NCT05327621Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamiparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sun Yat-sen University. Primary endpoint: Radiologic Progression-free Survival at 3 years. Status: unknown.
02
Drugs
pamiparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05327621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327621.